Myovant Sciences Ltd (NASDAQ:MYOV)‘s stock had its “buy” rating restated by research analysts at Cowen and Company in a research report issued to clients and investors on Tuesday.
MYOV has been the topic of several other research reports. Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 31st. Evercore ISI began coverage on Myovant Sciences in a research note on Wednesday, August 16th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $20.00.
Shares of Myovant Sciences (NASDAQ:MYOV) opened at 14.80 on Tuesday. The stock’s 50 day moving average price is $13.54 and its 200 day moving average price is $13.54. The firm’s market cap is $900.49 million. Myovant Sciences has a one year low of $10.25 and a one year high of $18.85.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/05/myovant-sciences-ltd-myov-rating-reiterated-by-cowen-and-company.html.
Several hedge funds and other institutional investors have recently made changes to their positions in MYOV. Wells Fargo & Company MN increased its stake in shares of Myovant Sciences by 331.9% during the first quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock worth $194,000 after purchasing an additional 12,700 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Myovant Sciences by 36.3% during the first quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock worth $279,000 after purchasing an additional 6,330 shares during the period. Oxford Asset Management bought a new position in shares of Myovant Sciences during the first quarter worth approximately $303,000. JPMorgan Chase & Co. increased its stake in shares of Myovant Sciences by 30.6% during the first quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock worth $975,000 after purchasing an additional 19,474 shares during the period. Finally, RA Capital Management LLC increased its stake in shares of Myovant Sciences by 56.6% during the first quarter. RA Capital Management LLC now owns 2,348,422 shares of the company’s stock worth $27,570,000 after purchasing an additional 848,422 shares during the period.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.